PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

EV889154197US

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/395 // (A61K 39/395, 37:02)	A1	(11) International Publication Number: **WO 95/09652** (43) International Publication Date: 13 April 1995 (13.04.95)

(21) International Application Number: PCT/GB94/00462

(22) International Filing Date: 10 March 1994 (10.03.94)

(30) Priority Data:
PCT/GB93/02070   6 October 1993 (06.10.93)   WO
(34) *Countries for which the regional or*
     international application was filed: GB et al.

(60) Parent Application or Grant
   (63) Related by Continuation
     US   PCT/GB93/02070 (CIP)
     Filed on   6 October 1993 (06.10.93)

(71) Applicant *(for all designated States except US)*: THE KENNEDY INSTITUTE FOR RHEUMATOLOGY [GB/GB]; 6 Bute Gardens, Hammersmith, London W6 7DW (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: FELDMANN, Marc [AU/GB]; 2 Church Road, Hampstead, London N6 4QT (GB). MAINI, Ravinder, Nath [GB/GB]; 151 Castelnau, Barnes, London SW13 9EW (GB). WILLIAMS, Richard, Owen [GB/GB]; 60 Cheverell House, Prichards Road, London E2 9BN (GB).

(74) Agents: HOLDCROFT, James, Gerald et al.; Graham Watt & Co., Riverhead, Sevenoaks, Kent TN13 2BN (GB).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

(57) Abstract

A method for treating autoimmune or inflammatory diseases, through the administration of a CD4+ T cell inhibiting agent, such as anti-CD4 antibody or cyclosporin A, in conjunction with or sequentially to a TNF antagonist, such as anti-TNF antibody or soluble TNF receptor, is disclosed. The method can be used to aid in therapy for humans and other mammals with a wide variety of autoimmune or inflammatory diseases.

TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
Description

Background of the Invention

The nature of autoantigens responsible for autoimmune
disorders is not known, nor is the action which triggers
the autoimmune response. One popular theory involves the
similarity of a viral protein to a self antigen, which
results in autoreactive T cells or B cells recognizing a
self antigen. Whereas B-lymphocytes produce antibodies,
thymus-derived or "T-cells" are associated with cell-
mediated immune functions. T-cells recognize antigens
presented on the surface of cells and carry out their
functions with these "antigen-presenting" cells.

Various markers have been used to define human T cell
populations. CD4 is a non-polymorphic surface
glycoprotein receptor with partial sequence identity to
immunoglobulins. CD4 receptors define distinct subsets of
mature peripheral T cells. In general, CD4 T cells
expressing helper or regulatory functions interact with B
cells in immune responses, while T cells expressing the
CD8 surface antigen function as cytotoxic T cells and have
regulatory effects on immune responses. Since T-cell
receptors are the pathway through which stimuli augment or
modulate T-cell responses, they present a potential target
for immunological intervention.

Of the cellular interactions, that of CD4+ T cells
with antigen presenting cells (APC) lies at the root of
the immune response. Many aspects of the autoimmune
response are essentially similar to that of normal immune
responses. Thus CD4+ autoantigen reactive T cells are
restimulated by APC expressing class II with autoantigen
peptides in the binding groove. In certain human diseases
the evidence that this occurs has been provided: in
Graves' disease of the thyroid, in vivo activated T cells

-2-

are present in the glands that are removed for refractory
disease, and many of these cells after cloning can be
shown to recognize autologous thyrocytes (as APC) not
extrinsically supplied with any antigen, or APC supplied
5   with the thyroid specific antigens thyroid peroxidase or
thyroglobulin (Londei, M. et al., Science 228: 85-89
(1985); Dayan, C.M. et al., Proc. Natl. Acad. Sci. USA 88:
7415-7419 (1991)). Similarly, in rheumatoid arthritis
(RA), in vivo activated T cells recognizing collagen type
10   II have been isolated from joints of an RA patient in
three consecutive operations during the course of three
years (Londei, M. et al., Proc. Natl. Acad. Sci. 86: 636-
640 (1989)). In other human diseases displaying
autoimmune characteristics, CD4+ T cells from the blood
15   have been cloned, including CD4+ T cells recognizing the
acetylcholine receptor in myasthenia gravis (Hohlfeld, R.
et al., Nature 310: 224-246 (1984)); myelin basic protein
in multiple sclerosis (Hafler, D.A. et al., J. Immunol.
139: 68-72 (1987)); or islet cell membranes in insulin
20   dependent diabetes mellitus (De Berardinis, P. et al.,
Lancet II: 823-824 (1988); Kontiainen, S. et al.,
Autoimmunity 8: 193-197 (1991)).

        Factors other than CD4 also influence cellular immune
response. The cytokine tumor necrosis factor-α (TNFα;
25   also termed cachectin) has multiple effects on
inflammation, tissue damage, immune response and cell
trafficking into lesions, and thus plays a role in the
pathogenesis of inflammatory joint diseases, including
rheumatoid arthritis (Brennan, F.M. et al., Lancet 11,
30   244-247 (1989); Feldmann, M. et al., Ann. Rheumatic Dis.
51: 480-486 (1990)). TNFα is a protein secreted primarily
by monocytes and macrophages in response to endotoxin or
other stimuli as a soluble homotrimer of 17 kD protein

subunits (Smith, R.A. *et al.*, *J. Biol. Chem. 262*: 6951-6954 (1987)). A membrane-bound 26 kD precursor form of TNF has also been described (Kriegler, M. *et al.*, *Cell 53*: 45-53 (1988). The expression of the gene encoding TNFα is
5   not limited to cells of the monocyte/macrophage family: TNF is also produced by CD4+ and CD8+ peripheral blood T lymphocytes, and by various cultured T and B cell lines (Cuturi, M.C. *et al.*, *J. Exp. Med. 165*: (1581 (1987); Sung, S.-S.J. *et al.*, *J. Exp. Med. 168*: 1539 (1988);
10 Turner, M. *et al.*, *Eur. J. Immunol. 17*: 1807-1814 (1987)). Recent evidence implicates TNF in the autoimmune pathologies and graft versus host pathology (Piguet, P.-F. *et al.*, *J. Exp. Med. 166*: 1280 (1987).

Because of the multiple factors involved in
15 autoimmune and inflammatory disorders, a great need exists for better therapies for autoimmune and inflammatory diseases.

Summary of the Invention

The current invention pertains to the discovery that
20 combination therapy, involving the use of a CD4+ T cell inhibiting agent in conjunction with a TNF antagonist, produces markedly superior results than the use of each agent alone in the treatment of autoimmune or inflammatory disease, particularly in rheumatoid arthritis. CD4+ T
25 cell inhibiting agents include agents which block, diminish, inhibit, or interfere with the activation of CD4+ T cells or the interaction of CD4+ T cells with antigen presenting cells (APC), such as antibodies to T cells or to their receptors; antibodies to APC or to their
30 receptors; and other appropriate peptides or small molecules. TNF antagonists include agents which block, diminish, inhibit, or interfere with TNF activity, TNF

-4-

receptors, or TNF synthesis, such as anti-TNF antibodies; soluble TNF receptors; and other appropriate peptides or small molecules.

In one embodiment of the current invention, anti-CD4
5   antibodies are administered in conjunction (either simultaneously or sequentially) with anti-TNF antibodies. In another embodiment of the current invention, anti-CD4 antibodies are administered in conjunction with soluble TNF receptor, such as a TNF receptor/TgG fusion protein.
10   In a third embodiment of the current invention, cyclosporin is administered in conjunction with anti-TNF antibody. The combination therapy can utilize any CD4+ T cell inhibiting agent in conjunction with any TNF antagonist, including multiple CD4+ T cell inhibiting
15   agents in conjunction with multiple TNF antagonists. Combination therapy can also utilize inflammatory mediators other than TNF antagonists, in conjunction with CD4+ T cell inhibiting agents.

The CD4+ T cell inhibiting agent and TNF antagonist
20   can be administered together with a pharmaceutically acceptable vehicle; administration can be in the form of a single dose, or a series of doses separated by intervals of days or weeks.

The benefits of combination therapy with CD4+ T cell
25   inhibiting agents and TNF antagonists include improved results in comparison with the effects of treatment with each therapeutic modality separately. In addition, lower dosages can be used to provide the same reduction of the immune and inflammatory response, thus increasing the
30   therapeutic window between a therapeutic and a toxic effect. Lower doses may also result in lower financial costs to the patient, and potentially fewer side effects.

-5-

Brief Description of the Figures

Figure 1 contains a set of graphs, individually
labelled as Fig. 1A and Fig. 1B, from an experiment which
illustrates the suppression of arthritis as assessed by
clinical score (Fig. 1A) and pawswelling measurements
(Fig. 1B) after the administration of 50 μg anti-TNF
(hamster TN3.19.2) and 200 μg anti-CD4 to DBA/1 male mice.
Open squares = control; diamonds = anti-CD4; triangles =
anti-TNF; closed squares = anti-CD4/anti-TNF.

Figure 2 contains a set of graphs, individually
labelled as Fig. 2A, Fig. 2B, Fig. 2C, and Fig. 2D, from a
second experiment which illustrates the potentiation of
anti-CD4 with low dose (50 μg) anti-TNF or high dose (300
μg) anti-TNF on clinical score and pawswelling
measurements. Fig. 2A: clinical score with low-dose
anti-TNF; Fig. 2B: clinical score with high-dose anti-
TNF; Fig. 2C: pawswelling with low-dose anti-TNF; Fig.
2D: pawswelling with high-dose anti-TNF. Open squares =
control; diamonds = anti-CD4; triangles = anti-TNF; closed
squares = anti-CD4/anti-TNF.

Figure 3 is a graph illustrating the suppression of
arthritis as assessed by pawswelling measurements after
the administration of 250 μg cyclosporin A, 50 μg anti-TNF
antibody, and a combination of 250 μg cyclosporin A and
50 μg anti-TNF antibody to DBA/1 mice. Open squares =
control; diamonds = cyclosporin A; triangles = anti-TNF;
closed squares = cyclosporin A/anti-TNF.

Detailed Description of the Invention

The present invention concerns the treatment of
autoimmune or inflammatory diseases, such as rheumatoid
arthritis, through the administration of a CD4+ T cell
inhibiting agent in conjunction with a TNF antagonist. The

-6-

invention also encompasses the use of multiple CD4+ T cell
inhibiting agents in conjunction with multiple TNF
antagonists. The term "CD4+ T cell inhibiting agent", as
used herein, refers to an agent which blocks, diminishes,
5   inhibits, or interferes with the activation of CD4+ T
cells or the interaction of CD4+ T cells with antigen
presenting cells (APC). CD4+ T cell inhibiting agents
include antibodies to T cells or to their receptors, such
as anti-CD4, anti-CD28, anti-CD52 (e.g., CAMPATH-1H) and
10 anti-IL-2R; antibodies to APC or to their receptors, such
as anti-class II, anti-ICAM-1, anti-LFA-3, and anti-LFA-1;
peptides and small molecules blocking the T cell/APC
interaction, including those which block the HLA class II
groove, or block signal transduction in T-cell activation,
15 such as cyclosporins, particularly cyclosporin A, or FK-
506; and antibodies to B cells including CD5+ B cells,
such as CD19, 20, 21, 23 and BB/7 or B1, ligands for CD28,
B cells including CD5+ B cells are considered to be an
important type of APC in disease processes (Plater-Zyberk,
20 C. et al., Ann. N.Y. Acad. Sci. 651: 540-555 (1992)), and
thus anti-B cell antibodies can be particularly useful in
the current invention.

The term "TNF antagonist", as used herein, refers to
an agent which blocks, diminishes, inhibits, or interferes
25 with TNF activity, TNF synthesis, or TNF receptors, such
as anti-TNF antibody; soluble TNF receptor (monomeric
receptor and/or fusion proteins comprising the receptor,
such as receptor/IgG fusion proteins, etc.); and other
appropriate peptides or small molecules, such as
30 pentoxyfilline or other phosphodiesterase inhibitors, and
thalidomide.

Inflammatory mediators other than TNF antagonists can
also be used instead of or in addition to TNF antagonists

-7-

in the current invention. In rheumatoid joint cell
cultures, Brennan et al. (Lancet ll, 244-247 (1989)) have
shown that blocking TNF results in down-regulation of IL-1
production, and down-regulation of the pro-inflammatory

5   cytokine GM-CSF (Haworth et al., E.J.I. 21:2575-2579
(1991); Brennan et al., in preparation). Unpublished data
indicates that anti-TNF also blocks IL-6 production.
These cytokine "networks" or "hierarchies" also operate in
vivo; rheumatoid arthritis patients treated with anti-TNF

10   antibody reduced their serum IL-6 levels, as well as
levels of IL-6 dependent acute phase proteins such as C
reactive protein, in the weeks following treatment
(Elliott, M.J. et al., Arthritis & Rheumatism 36:1681-1690
(1993)). Since the pro-inflammatory mediators TNF, IL-1,

15   GM-CSF, IL-6 and IL-8 are part of the same network or
hierarchy, blocking any of these could have comparable
effects and thus can be used as the inflammatory mediators
of the current invention. Representative inflammatory
mediators include agents which block, diminish, inhibit,

20   or interfere with IL-1 activity, synthesis, or receptor
signalling, such as anti-IL-1 antibody, soluble IL-1R, IL-
1 receptor antagonist, or other appropriate peptides and
small molecules; agents which block, diminish, inhibit, or
interfere with IL-6 activity, synthesis, or receptor

25   signalling, such as anti-IL-6 antibody, anti-gp 130, or
other appropriate peptides and small molecules; modalities
which block, diminish, inhibit, or interfere with the
activity, synthesis, or receptor signalling of other
inflammatory mediators, such as GM-CSF and members of the

30   chemokine (IL-8) family; and cytokines with anti-
inflammatory properties, such as IL-4, IL-10, and TGFβ.
In addition, other anti-inflammatory agents, such as the
anti-rheumatic agent methotrexate, can be administered in

-8-

conjunction with the CD4+ T cell inhibiting agent and/or
the TNF antagonist.

In one embodiment of the current invention, anti-CD4
antibody is used in conjunction with anti-TNF antibody.
5   The term antibody is intended to encompass both polyclonal
and monoclonal antibodies. The term antibody is also
intended to encompass mixtures of more than one antibody
reactive with CD4 or with TNF (e.g., a cocktail of
different types of monoclonal antibodies reactive with CD4
10 or with TNF). The term antibody is further intended to
encompass whole antibodies, biologically functional
fragments thereof, bifunctional antibodies, and chimeric
antibodies comprising portions from more than one species.
Biologically functional antibody fragments which can be
15 used are those fragments sufficient for binding of the
antibody fragment to CD4 or to TNF.

The chimeric antibodies can comprise portions derived
from two different species (e.g., human constant region
and murine variable or binding region). The portions
20 derived from two different species can be joined together
chemically by conventional techniques or can be prepared
as single contiguous proteins using genetic engineering
techniques. DNA encoding the proteins of both the light
chain and heavy chain portions of the chimeric antibody
25 can be expressed as contiguous proteins.

Monoclonal antibodies reactive with CD4 or with TNF
can be produced using somatic cell hybridization
techniques (Kohler and Milstein, Nature 256: 495-497
(1975)) or other techniques. In a typical hybridization
30 procedure, a crude or purified protein or peptide
comprising at least a portion of CD4 or of TNF can be used
as the immunogen. An animal is vaccinated with the

-9-

immunogen to obtain anti-CD4 or anti-TNF antibody-
producing spleen cells. The species of animal immunized
will vary depending on the species of monoclonal antibody
desired. The antibody producing cell is fused with an
5   immortalizing cell (e.g., myeloma cell) to create a
hybridoma capable of secreting anti-CD4 or anti-TNF
antibodies. The unfused residual antibody-producing cells
and immortalizing cells are eliminated. Hybridomas
producing desired antibodies are selected using
10   conventional techniques and the selected hybridomas are
cloned and cultured.

Polyclonal antibodies can be prepared by immunizing
an animal with a crude or purified protein or peptide
comprising at least a portion of CD4 or of TNF. The
15   animal is maintained under conditions whereby antibodies
reactive with either CD4 or TNF are produced. Blood is
collected from the animal upon reaching a desired titre of
antibodies. The serum containing the polyclonal
antibodies (antisera) is separated from the other blood
20   components. The polyclonal antibody-containing serum can
optionally be further separated into fractions of
particular types of antibodies (e.g., IgG, IgM).

Antibodies specific for CD4 have been used in
treatment of a wide range of both experimentally-induced
25   and spontaneously-occurring autoimmune diseases. A more
detailed description of anti-CD4 antibodies and their use
in treatment of disease is contained in the following
references, the teachings of which are hence incorporated
by reference: U.S. Application NO. 07/867,100, filed June
30   25, 1992; Grayheb, J. et al., J. of Autoimmunity 2:627-642
(1989); Ranges, G.E. et al, J. Exp. Med. 162: 1105-1110
(1985); Hom, J.T. et al., Eur. J. Immunol. 18: 881-888
(1988); Wooley, P.H. et al., J. Immunol. 134: 2366-2374

-10-

(1985); Cooper, S.M. _et al._, _J. Immunol. 141_: 1958-1962
(1988); Van den Broek, M.F. _et al._, _Eur. J. Immunol. 22_:
57-61 (1992); Wofsy, D. _et al._, _J. Immunol. 134_: 852-857
(1985); Wofsy, D. _et al._, _J. Immunol. 136_: 4554-4560
5   (1986); Ermak, T.J. _et al._, _Laboratory Investigation 61_:
447-456 (1989); Reiter, C. _et al._, 34:525-532 (1991);
Herzog, C. _et al._, _J. Autoimmun._ 2:627 (1989); Ouyang, Q.
_et al._, _Dig. Dis. Sci._ 33:1528-1536 (1988); Herzog, C. _et_
_al._, _Lancet_, p. 1461 (December 19, 1987); Emmrich, J. _et_
10   _al._, _Lancet_ 338:570-571 (August 31, 1991).

A more detailed description of anti-TNF antibodies
and their use in treatment of disease is contained in the
following references, the teachings of which are hence
incorporated by reference: U.S. Application No.
15   07/943,852, filed September 11, 1992; Rubin _et al._, (EPO
Patent Publication 0218868, April 22, 1987); Yone _et al._,
(EPO Patent Publication 0288088, October 26, 1988); Liang,
C.-M. _et al._, _Biochem. Biophys. Res. Comm._ 137:847-854
(1986); Meager, A. _et al._, _Hybridoma_ 6:305-311 (1987);
20   Fendly _et al._, _Hybridoma_ 6:359-369 (1987); Bringman, T.S.
_et al._, _Hybridoma_ 6:489-507 (1987); Bringman T.S. _et al._,
Hybridoma 6:489-507 (1987); Hirai, M. _et al._, _J. Immunol._
Meth. 96:57-62 (1987); Moller, A. _et al._, _Cytokine_ 2:162-
169 (1990); Mathison, J.C. _et al._, _J. Clin. Invest._
25   81:1925-1937 (1988); Beutler, B. _et al._, _Science_ 229:869-
871 (1985); Tracey, K.J. _et al._, _Nature_ 330:662-664
(1987); Shimamoto, Y. _et al._, _Immunol. Lett._ 17:311-318
(1988); Silva, A.T. _et al._, _J. Infect. Dis._ 162: 421-427
(1990); Opal, S.M. _et al._, _J. Infect. Dis._ 161:1148-1152
30   (1990); Hinshaw, L.B. _et al._, _Circ. Shock_ 30:279-292
(1990); _Lancet_ 342:173-174 (1993); Williams, R.O. _et al._,
Proc. Natl. Acad. Sci. USA 89:9784-9788 (1992).

-11-

The CD4+ T cell inhibiting agent and TNF antagonist
can be administered by various routes, including
subcutaneously, intravenously, intramuscularly, topically,
orally, rectally, nasally, buccally, vaginally, by

5   inhalation spray, or via an implanted reservoir in dosage
formulations containing conventional non-toxic
pharmaceutically-acceptable carriers, adjuvants and
vehicles. The form in which the agents are administered
(e.g., capsule, tablet, solution, emulsion) will depend at

10   least in part on the route by which it is administered.
A therapeutically effective amount of the combination
of anti-CD4 agent and anti-TNF agent is that amount
necessary to significantly reduce or eliminate symptoms
associated with a particular autoimmune or inflammatory

15   disorder. The therapeutically effective amount will be
determined on an individual basis and will be based, at
least in part, on consideration of particular agents used,
the individual's size, the severity of symptoms to be
treated, the result sought, etc. In one embodiment, for

20   example, the preferred therapeutically effective amount of
anti-CD4 antibody administered in conjunction with anti-
TNF antibody is in the range of 0.1 - 10 mg/kg/dose of
each antibody. Thus, the therapeutically effective amount
can be determined by one of ordinary skill in the art

25   employing such factors and using no more than routine
experimentation.
The therapeutically effective amount can be
administered in the form of a single dose, or a series of
doses separated by intervals of days or weeks. Once the

30   therapeutically effective amount has been administered, a
maintenance amount of anti-CD4 agent, of anti-TNF agent,
or of a combination of anti-CD4 agent and anti-TNF agent
can be administered. A maintenance amount is the amount

-12-

of anti-CD4 agent, anti-TNF agent, or combination of anti-
CD4 agent and anti-TNF agent necessary to maintain the
reduction or elimination of symptoms achieved by the
therapeutically effective dose. The maintenance amount
5   can be administered in the form of a single dose, or a
series or doses separated by intervals of days or weeks.
Like the therapeutically effective amount, the maintenance
amount will be determined on an individual basis.

      The combination therapy of the current invention is
10   thus useful for the treatment of many autoimmune or
inflammatory diseases of humans and of animals.   In
humans, diseases for which the therapy is appropriate
include rheumatoid arthritis (RA) and juvenile chronic
arthritis (JCA). Other diseases and conditions for which
15   combination therapy is appropriate include
spondyloarthropathies, such as ankylosing spondylitis,
psoriatic arthritis, or arthritis associated with
inflammatory bowel disease; vasculitides, such as
polyarteritis nodosa, Wegener's granulomatosis, giant cell
20   arteritis, Henoch-Schoenlein purpura, and microscopic
vasculitis of the kidneys; Sjogren's syndrome; systemic
lupus erythematosus; inflammatory bowel disease, including
Crohn's disease and ulcerative colitis; chronic active
hepatitis; primary biliary cirrhosis; cryptogenic
25   fibrosing alveolitis and other fibrotic lung diseases;
uveitis; multiple sclerosis; myasthenia gravis; hemolytic
anemia; scleroderma; graft versus host disease; allergy;
and transplantation of kidneys, liver, heart, lungs, bone
marrow, skin, or of other organs.
30

      The invention is further and more specifically
illustrated by the following Examples.

-13-

EXAMPLE 1 Treatment of Induced Arthritis in a Murine Model
              using Anti-CD4 Antibody and Anti-TNF Antibody

The murine model of collagen type II induced
arthritis has similarities to rheumatoid arthritis (RA) in
5   its marked MHC class II predisposition, as well as in
histology, immunohistology, and erosions of cartilage and
bone. Furthermore, there is a good correlation of
therapeutic response with human rheumatoid arthritis. For
example, in both diseases anti-TNF antibody has beneficial
10   effects (Williams, R.O. et al., PNAS 89:9784-9788 (1992);
Elliott, M. J. et al., Arthritis & Rheumatism 36:1681-90
1993), and anti-CD4 antibody has minimal effect (Williams,
R.O. et al., PNAS (in press) (1994); and Horneff, G. et
al., Arthritis & Rheumatism 1991:34-129 (1992)). Thus the
15   animal model serves as a good approximation to human
disease.

The model of rheumatoid arthritis used herein is
described by Williams, R.O. et al., (PNAS, 89:9784-9788
(1992), i.e., the collagen type II induced arthritis in
20   the DBA/1 mouse. Type II collagen was purified from
bovine articular cartilage by limited pepsin
solubilization and salt fractionation as described by
Miller (Biochemistry 11:4903-4909 (1972)).

A.   Study 1
25   Male DBA/1 mice were immunized intradermally at 8-12
weeks of age with 100 µg of bovine type II collagen
emulsified in complete Freund's adjuvant (Difco
Laboratories, East Molsey, UK), and 21 days later with 100
µg of collagen intra-peritoneally (i.p.). Immediately
30   after the onset of clinically evident arthritis (redness
and/or swelling in one or more limbs), which was about 35
days after the initial injection, mice were injected i.p.

-14-

with anti-CD4; anti-TNF; anti-CD4 and anti-TNF; or isotype
controls. Arthritis was monitored for clinical score and
paw-swelling for 10 days. Antibody treatment was
administered on day 1 (onset), day 4 and
5   day 7.

Clinical Score and Pawswelling

Two experiments were completed, assessing clinical
score and pawswelling. In each, 200 μg of anti-CD4 were
used per injection (rat YTS 191 and YTA 3.1) was used.
10 Clinical score was assessed on the following scale: 0 =
normal; 1 = slight swelling and/or erythema; 2 =
pronounced edematoma swelling; and 3 = joint rigidity.
Each limb was graded, giving a maximum score of 12 per
mouse. Pawswelling was monitored by measuring the
15 thickness of each affected hind paw with calipers. The
results were expressed as the percentage increment in paw
width relative to the paw width before the onset of
arthritis.

In the first experiment, a single dose of 50 μg per
20 injection of anti-TNF (hamster TN3.19.2) was administered
to each of five mice per group. There was no significant
effect of anti-CD4 or anti-TNF (TN3.19 given 3 times at 50
μg/mouse). Hence the benefit of combination therapy, in
both clinical score and footpad swelling, is readily seen
25 (see Figures 1A, 1B).

In the second experiment, either 50 μg or 300 μg of
anti-TNF were administered to each of 7 mice per group.
Both anti-CD4 and anti-TNF at low (50 μg) concentration
had some effect, and benefit of combination therapy of
30 these two concentrations was noted in pawswelling, not in
clinical score. However, if anti-TNF was injected at

-15-

300 μg/mouse, the benefit of combination therapy with
anti-CD4 was seen in both clinical score and more clearly
in paw-swelling (see Figures 2A, 2B, 2C, 2D).

   The results of the experiments indicate that there is
5 a clear benefit to combination therapy with anti-TNF and
anti-CD4 antibodies, as measured by clinical score and
foot pad swelling.

B.   Study 2

   Male DBA/1 mice were immunized intradermally at 8-12
10 weeks of age with 100 μg type II collagen emulsified in
Freund's complete adjuvant (Difco Laboratories, East
Molsey, UK). Day one of arthritis was considered to be
the day that erythema and/or swelling was first observed
in one or more limbs. Arthritis became clinically evident
15 around 30 days after immunization with type II collagen.
For each mouse, treatment was started on the first day
that arthritis was observed and continued over a 10 day
period, after which the mice were sacrificed and joints
were processed for histology. Monoclonal antibody (mAb)
20 treatment was administered on days 1, 4, and 7. For anti-
TNF antibody, TN3-19.12, a neutralizing hamster IgG1 anti-
TNFα/β monoclonal antibody (mAb), was used (Sheehan, K. C.
et al., J. Immunology 142:3884-3893 (1989)). The isotype
control was L2. The anti-TNF antibody and the isotype
25 control were provided by R. Schreiber, Washington
University Medical School (St. Louis, MO, USA), in
conjunction with Celltech (Slough, UK). The cell-
depleting anti-CD4 monoclonal antibody (rat IgG2b)
consisted of a 1:1 mixture of YTS 191.1.2 and YTA 3.1.2,
30 provided by H. Waldmann (University of Cambridge, UK)
(Galfre, G. et al., Nature 277: 131-133 (1979); Cobbold,

-16-

S.P. et al., Nature 312: 548-551 (1984); Qin, S. et al.,
European J. Immunology 17:1159-1165 (1987)).

Paw-Swelling

First, a sub-optimal dose of 50 µg of anti-TNF alone
5   was compared with the same dose given together with 200 µg
of anti-CD4. To verify the results, two separate but
identical experiments were carried out (11-12 mice/group
and 7-8 mice/group, respectively). Neither anti-CD4 alone
nor sub-optimal anti-TNF alone were able to significantly
10   reduce paw-swelling (data not shown). However, treatment
with anti-TNF and anti-CD4 resulted in a consistently and
statistically significant reduction in paw-swelling
relative to the group given control mAb (P < 0.001).
Furthermore, in both experiments, combined anti-TNF/anti-
15   CD4 treatment (also referred to herein as anti-CD4/TNF
treatment) produced a significant reduction in paw-
swelling relative to anti-CD4 alone, and anti-TNF alone
(P < 0.05).

Next, an optimal dose of anti-TNF (300 µg) alone was
20   compared in two separate but identical experiments (7-7
mice/group and 6-7 mice/group, respectively) with the same
dose given in combination with anti-CD4. As before, the
combined anti-TNF/anti-CD4 treatment resulted in a
significant reduction in paw-swelling compared to
25   treatment with the control mAb (P <0.005; data not shown).
In the first experiment, paw-swelling was also
significantly reduced in the combined anti-CD4/anti-TNF
treated group relative to the groups given anti-CD4 alone
or anti-TNF alone (P < 0.05). Some reduction in paw-
30   swelling was observed in mice given either anti-TNF alone
or anti-CD4 alone although the differences were not
significant, possibly because of the small group sizes (6

-17-

per group). In the second experiment, combined anti-
CD4/anti-TNF gave significantly reduced paw-swelling
compared to anti-CD4 alone (P < 0.05) but not compared to
anti-TNF alone since anti-TNF itself caused a significant
5   reduction in paw-swelling, as expected from previous work
(Williams, R.O. et al., PNAS 89: 9784-9788 (1992)). In
the experiments, the reduction in paw-swelling
attributable to anti-TNF alone was 23% and 33%,
respectively. Thus, the reduction in paw-swelling
10 attributable to anti-TNF treatment was broadly comparable
with our previously published findings in which treatment
with TN3-119.12 (300 μg/mouse) resulted in a mean
reduction in paw-swelling over the treatment period of
around 34% relative to controls (Williams, R.O. et al.,
15 PNAS 89: 9784-9788 (1992)).

Limb Involvement

In collagen-induced arthritis, as in RA,it is usual
for additional limbs to become involved after the initial
appearance of clinical disease and new limb involvement is
20 an important indicator of the progression of the disease.
To determine the effect of anti-CD4/anti-TNF treatment on
new limb involvement, the number of limbs with clinically
detectable arthritis at the end of the 10 day treatment
period was compared with the number of arthritis limbs
25 before treatment. In mice given the control mAb there was
an increase in limb involvement over the 10 day period of
approximately 50% The results from the two experiments
were pooled, and are shown in Table 1.

-18-

Table 1:   Combined anti-CD4/anti-TNF Inhibits Progression
of Clinical Arthritis

Treatment	Number of Limbs Affected (Mean ± SEM)		Increase (%)
	Day 1	Day 10	
Sub-optimal anti-TNF (50 µg)			
anti-CD4 (n=18)	1.30 ± 0.10	1.90 ± 0.13	46.1
anti-TNF (n=19)	1.20 ± 0.09	1.65 ± 0.17	37.5
anti-CD4/TNF (n=18)	1.40 ± 0.09	1.45 ± 0.22	3.4[1]
control mAb (n=18)	1.43 ± 0.15	2.24 ± 0.18	56.6
Optimal anti-TNF (300 µg)			
anti-CD4 (n=12)	1.27 ± 0.10	1.80 ± 0.14	42.0
anti-TNF (n=11)	1.50 ± 0.17	1.64 ± 0.20	9.5[2]
anti-CD4/TNF (n=13)	1.25 ± 0.11	1.25 ± 0.11	0[3]
control mAb (n=12)	1.53 ± 0.19	2.27 ± 0.25	47.8

[1] $P < 0.05$ (anti-CD4/TNF vs. control mAb)
[2] $P < 0.05$ (anti-TNF vs. control mAb)
[3] $P < 0.005$ (anti-CD4/TNF vs. control mAb)

There was some reduction in new limb involvement in the groups given anti-CD4 alone and sub-optimal anti-TNF alone, although the differences were not significant. In the group given optimal anti-TNF the increase in limb
5   involvement was less than 10% (P < 0.05). More striking, however, was the almost complete absence of new limb involvement in the groups given combined anti-CD4/anti-TNF. Thus, the increase in new limb involvement was only 3% in mice given anti-CD4 plus suboptimal anti-TNF
10   (P < 0.05) and 0% in mice given anti-CD4 plus optimal anti-TNF (P < 0.005).

Histology
        After 10 days, the mice were sacrificed; the first limb that had shown clinical evidence of arthritis was
15   removed from each mouse, formalin-fixed, decalcified, and wax-embedded before sectioning and staining with haematoxylon and eosin. A sagittal section of the proximal interphalangeal (PIP) joint of the middle digit was studied in a blind fashion for the presence or absence
20   of erosions in either cartilage or bone (defined as demarcated defects in cartilage or bone filled with inflammatory tissue). The comparisons were made only between the same joints, and the arthritis was of identical duration. Erosions were observed in almost 100%
25   of the PIP joints from the control groups and in approximately 70-80% of the joints given either anti-CD4 alone or sub-optimal anti-TNF alone. The results of the two experiments were pooled, and are shown in Table 2.

-20-

Table 2:   Proportions of PIP Joints Showing
             Significant Erosion of Cartilage and/or
             Bone

Treatment	Joints with Erosions
Sub-optimal anti-TNF (50 μg)	
anti-CD4	13/18 (72%)
anti-TNF	14/19 (74%)
anti-CD4/TNF	4/18 (22%)[1]
control mAb	17/18 (94%)
Optimal anti-TNF (300 μg)	
anti-CD4	10/12 (83%)
anti-TNF	6/11 (54%)[2]
anti-CD4/TNF	4/13 (31%)[3]
control mAb	12/12 (100%)

[1] $P < 0.01$ (anti-CD4/TNF vs. anti-CD4 alone; anti-TNF
     alone and control mAb)
[2] $P < 0.01$ (anti-TNF alone vs. control mAb)
[3] $P < 0.01$ (anti-CD4/TNF vs. anti-CD4 alone and control
     mAb)

An optimal dose of anti-TNF alone significantly reduced
pathology, as reported previously (Williams, R.O. et al.,
PNAS 89: 9784-9788 (1992)). Thus, in the mice given
optimal anti-TNF alone the proportion of joints showing
erosive changes was reduced to 54% ($P < 0.001$) whereas in
the groups given anti-CD4 plus either sub-optimal or
optimal anti-TNF, only 22% ($P < 0.01$) and 31%
($P > 0.01$) of the joints, respectively, were eroded.
Thus, 300 μg of anti-TNF alone gave a degree of protection
against joint erosion but combined anti-CD4/anti-TNF
provided significantly greater protection.

Depletion of CD4+ T Cells

The extent to which anti-CD4 treatment depleted peripheral CD4+ T cells was determined by flow cytometry. To enumerate the proportion of CD4+ lymphocytes in
5 disassociated spleen populations or peripheral blood, cells were incubated with phycoerythrin-conjugated anti-CD4 (Becton Dickinson, Oxford, UK), then analyzed by flow cytometry (FACScan, Becton Dickinson) with scatter gates set on the lymphocyte fraction. Anti-CD4 treatment
10 resulted in 98% (± 1%) depletion of CD4+ T cells in the spleen and 96% (± 3%) depletion of CD4+ T cells in the blood.

Immunohistochemistry

The possible persistence of CD4+ T cells in the joint
15 despite virtual elimination of peripheral CD4+ T cells was next investigated by immunohistochemical analysis of sections from treated arthritic mice. Wax-embedded sections were de-waxed, trypsin digested, then incubated with anti-CD4 mAb (YTS 191.1.2/YTA 3.1.2). To confirm the
20 T cell identity of the CD4+ T cells, sequential sections were stained with anti-Thy-1 mAb (YTS 154.7) (Cobbold, S.P. et al., Nature 312:548-551 (1984)). Control sections were incubated with HRPN11/12a. Detection of bound antibody was by alkaline phosphatase/rat anti-alkaline
25 phosphatase complex (APAAP; Dako, High Wycombe, UK) and fast red substrate as described (Deleuran, B.W. et al., Arthritis & Rheumatism 34:1125-1132 (1991)). Small numbers of CD4+ T cells were detected in the joints, not only of mice given control mAb, but also of those treated
30 with anti-CD4 (data not shown). Furthermore, within the small number of mice that were studied (four per treatment group), it was not possible to detect significantly

-22-

reduced numbers of CD4+ T cells in the groups given anti-
CD4 alone or anti-CD4 plus anti-TNF (data not shown).
Anti-CD4 treatment did not, therefore, eliminate CD4+ T
cells from the joint.

5   Anti-collagen IgG Levels

Serum anti-collagen IgG levels were measured by
enzyme-linked immunosorbent assay (ELISA). Microtitre
plates were coated with bovine type II collagen (2 μg/ml),
blocked, then incubated with test sera in serial dilution
10 steps. Detection of bound IgG was by incubation with
alkaline phosphatase-conjugated goat anti-mouse IgG,
followed by substrate (dinitrophenol phosphate). Optical
densities were read at 405 nm. A reference sample,
consisting of affinity-purified mouse anti-type II
15 collagen antibody, was included on each plate. Results
are shown in Table 3.

-23-

Table 3:   Serum Levels of Anti-type II collagen IgG

Treatment	Anti-collagen IgG (Mean ± SEM) (µg/ml)
Sub-optimal anti-TNF (50 µg)	
anti-CD4 (n=18)	285 ± 37
anti-TNF (n=19)	208 ± 29
anti-CD4/TNF (n=18)	208 ± 34
control mAb (n=18)	238 ± 36
Optimal anti-TNF (300 µg)	
anti-CD4 (n=12)	288 ± 39
anti-TNF (n=11)	315 ± 49
anti-CD4/TNF (n=13)	203 ± 33
control mAb (n=12)	262 ± 47

Serum levels of anti-type II collagen IgG were not
significantly altered within the 10 day treatment period
by anti-CD4 alone, anti-TNF alone, or anti-CD4 plus anti-
TNF.

Anti-Globulin Response

To find out whether anti-CD4 treatment prevented a
neutralizing anti-globulin response against the anti-TNF
mAb, IgM anti-TN4-19.12 levels on day 10, as measured by
ELISA, were compared. At this time, an IgG anti-TN3-19.12
response was not detected. Microtitre plates were coated
with TN3-19.12 (5 µg/ml), blocked, then incubated with
serially diluted test sera. Bound IgM was detected by
goat anti-mouse IgM-alkaline phosphatase conjugate,
followed by substrate. The results demonstrated that
anti-CD4 was highly effective in preventing the
development of an anti-TN3-19.12 antibody response (Table

-24-

4). Next, to determine whether anti-CD4 treatment led to
increased levels of circulating anti-TNF-α (by reducing
the antibody response to the hamster anti-TNF), an ELISA
was carried out in which recombinant murine TNF-α was used
5 to detect free TN3-19.12 in the sera of mice on day 10 of
the experiment. Microtitre plates were coated with
recombinant murine TNF-α, blocked, then incubated with
test sera. Goat anti-hamster IgG-alkaline phosphatase
conjugate (adsorbed against murine IgG) was then applied,
10 followed by substrate. Quantitation was by reference to a
sample of known concentration of TN3-19.12. Results are
shown in Table 4.

Table 4: IgM anti-TN3 Titres and Levels of Unbound TN3

Treatment	Reciprocal of Anti-TN3 Titre (Mean)	Unbound TN3 (Mean ± SEM) (μg/ml)
Sub-optimal anti-TNF (50 μg)		
anti-TNF (n = 12)	242	8.6 ± 2.0
anti-CD4/TNF (n = 12)	84[1]	12.1 ± 1.9
Optimal anti-TNF (300 μg)		
anti-TNF (n = 12)	528	90.7 ± 11.9
anti-CD4/TNF (n = 12)	91[1]	102.7 ± 12.5

[1] Significantly reduced anti-TN3 titre ($P < 0.005$)

Levels of TN3-19.12 were slightly elevated in the groups
given anti-CD4 plus anti-TNF compared to anti-TNF alone,
although the differences were not significantly different.

-25-

EXAMPLE 2 Treatment of Induced Arthritis in a Murine Model using TNF Receptor/IgG Fusion Protein with Anti-CD4 Antibody

The murine model of collagen type II induced
5 arthritis, described above, was used to investigate the efficacy of a human p55 TNF receptor/IgG fusion protein, in conjunction with anti-CD4 monoclonal antibody (mAb), for its ability to modulate the severity of joint disease in collagen-induced arthritis. First, a comparison was
10 made between the efficacy of TNF receptor/IgG fusion protein treatment, anti-TNF mAb treatment, and high dose corticosteroid therapy. Subsequently, therapy with TNF receptor/IgG fusion protein in conjunction with anti-CD4 antibody was investigated.

15 A. Experimental Procedure

Male DBA/1 mice were immunized intradermally with 100 μg of bovine type II collagen emulsified in complete Freund's adjuvant (Difco Laboratories, East Molsey, UK). The mean day of onset of arthritis was approximately one
20 month after immunization. After the onset of clinically evident arthritis (erythema and/or swelling), mice were injected intraperitoneally with therapeutic agents. Arthritis was monitored for clinical score and paw swelling (measured with calipers) for 10 days, after which
25 the mice were sacrificed and joints were processed for histology. Sera were collected for analysis on day 10. Therapeutic agents were administered on day 1 (onset), day 4 and day 7. The therapeutic agents included TNF receptor/IgG fusion protein (p55-sf2), anti-TNF antibody,
30 anti-CD4 antibody, and methylprednisolone acetate.

-26-

B. Comparison of Treatment with TNF Receptor/IgG Fusion
    Protein, Anti-TNF Antibody, or Methylprednisolone
    Acetate

        Using the Experimental Procedure described above,
5   groups of mice were subjected to treatment with TNF
    receptor/IgG protein (2 μg) (18 mice), TNF receptor/IgG
    protein (20 μg) (18 mice), TNF receptor/IgG protein
    (100 μg) (12 mice), anti-TNF monoclonal antibody (mAb)
    (300 μg) (17 mice), methylprednisolone acetate (6 mice),
10 an irrelevant human IgG1 monoclonal antibody (mAb) (6
    mice), or saline (control). The TNF receptor/IgG fusion
    protein, herein referred to as p55-sf2, (Butler et al.,
    Cytokine (in press): (1994)), was provided by Centocor,
    Inc., Malvern PA; it is dimeric and consists of the human
15 p55 TNF receptor (extracellular domains) fused to a
    partial J sequence followed by the whole of the constant
    region of the human IgG1 heavy chain, itself associated
    with the constant region of a kappa light chain. The
    anti-TNF antibody was TN3-19.12, a neutralizing hamster
20 IgG1 anti-TNFα/β monoclonal antibody (Sheehan, K. C. et
    al., J. Immunology 142:3884-3893 (1989)), and was provided
    by R. Schreiber, Washington University Medical School (St.
    Louis, MO, USA), in conjunction with Celltech (Slough,
    UK). Neutralizing titres were defined as the
25 concentration of TNFα neutralizing agent required to cause
    50% inhibition of killing of WEHI 164 cells by trimeric
    recombinant murine TNFα; the neutralizing titre of p55-sf2
    was 0.6 ng/ml, compared with 62.0 ng/ml for anti-TNF mAb
    (TN3-19.12), using 60 pg/ml mouse TNFα. The
30 corticosteroid, methyl-prednisolone acetate (Upjohn,
    Crawley, UK) was administered by intraperitoneal injection
    as an aqueous suspension at a dosage level of 2 mg/kg body
    weight; using the protocol described above, this dosage is

-27-

equivalent to 4.2 mg/kg/week, a dose which is higher than the typical dose used to treat refractory RA in humans (1-2 mg/kg/week).

Paw-Swelling

5   Treatment with p55-sf2 resulted in a dose-dependent reduction in paw-swelling over the treatment period, with the doses of 20 μg and 100 μg giving statistically significant reductions in paw-swelling relative to mice given saline (P < 0.05). The group of mice given an
10 irrelevant human IgG1 mAb as a control did not show any deviation from the saline-treated group (data not shown), indicating that the therapeutic effects of p55-sf2 were attributable to the TNF receptor rather than the human IgG1 constant region. Similar reductions in paw-swelling
15 were seen in mice given 300 μg of anti-TNF mAb as in those given 100 μg of p55-sf2, although anti-TNF mAb was marginally more effective than p55-sf2 at inhibiting paw-swelling. A reduction in paw-swelling was observed in the methylprednisolone acetate treated group that was
20 comparable in magnitude to the reductions given p55-sf2 at 100 μg or anti-TNF mAb at 300 μg.

Limb Involvement

       The change in the number of arthritic limbs over the 10 day treatment period was examined. Results are shown
25 in Table 5.

-28-

Table 5: Inhibitory Effect of TNF-Targeted Therapy on Limb Recruitment

Treatment (number of animals)	Limbs Affected (mean ± SEM)		Increase (%)
	Day 1	Day 10	
saline (n = 12)	1.33 ± 0.14	2.25 ± 0.18	69%
p55-sf2, 2 μg (n = 18)	1.28 ± 0.11	1.94 ± 0.17	51%
p55-sf2, 20 μg (n = 18)	1.37 ± 0.11	1.79 ± 0.16	31%
p55-sf2, 100 μg (n = 12)	1.17 ± 0.17	1.58 ± 0.23	35%
Control IgG1, 100 μg (n = 6)	1.00 ±0.00	0.15 ± 0.22	50%
Anti-TNF mAb, 300 μg (n = 17)	1.47 ± 0.15	1.76 ± 0.16[1]	20%
Methylprednisolone acetate (n = 6)	1.00 ± 0.00	1.50 ± 0.22	33%

[1] $P < 0.05$ (vs. saline; Mann Whitney Test)

A strong trend towards reduced limb recruitment was seen
in the groups of mice given p55-sf2, anti-TNF mAb or
methylprednisolone acetate, but only in the anti-TNF mAb
treated group did the reduction reach statistical
significance ($P < 0.05$).

Histology

After 10 days, the mice were sacrificed; the first
limb to show clinical evidence of arthritis was removed
from each mouse, fixed, decalcified, wax-embedded, and
sectioned and stained with haematoxylon and eosin.
Sagittal sections of the proximal interphalangeal (PIP)
joint of the middle digit of each mouse were studied in a

blind fashion and classified according to the presence or absence of erosions, as defined above. Comparisons were thus made between identical joints, and the arthritis was of equal duration. Results are shown in Table 6.

5 **Table 6: Histopathology of PIP Joints**

Treatment	PIP Joints with Erosions
Saline	11/12 (92%)
p55-sf2, 2 μg	14/18 (78%)
p55-sf2, 20 μg	14/18 (78%)
p55-sf2, 100 μg	6/12 (50%)[1]
Control IgG1, 100 μg	6/6 (100%)
Anti-TNF mAb, 300 μg	7/17 (41%)[2]
Methylprednisolone acetate	4/6 (67%)

[1] $P < 0.05$ (vs. saline).
15 [2] $P < 0.01$ (vs. saline). Data were compared by Chi-square analysis.

Erosions were present in 92% and 100% of the PIP joints in the saline treated group and the control human IgG1 treated group, respectively. However, only 50%
20 ($P < 0.05$) of joints from the mice treated with p55-sf2 (100 μg) and 41% ($P < 0.01$) of mice given anti-TNF mAb exhibited erosive changes. Some reductions in the proportion of eroded joints were observed in mice treated with 2 μg or 20 μg of p55-sf2, but these were not
25 statistically significant. Similarly, treatment with methylprednisolone acetate did not significantly reduce joint erosion.

-30-

Anti-Collagen Antibody Levels

Anti-collagen IgG levels on day 10 were measured by
ELISA as described (Williams, R.O. et al., PNAS 89: 9784-
9788 (1992)). Microtitre plates were sensitized with type
5 II collagen, then incubated with serially-diluted test
sera. Bound IgG was detected using alkaline phosphatase-
conjugated goat anti-mouse IgG, followed by substrate
(dinitrophenol phosphate). Optical densities were read at
405 nm. No differences between any of the treatment
10 groups were detected (data not shown). this suggests that
the therapeutic effect of p55-sf2 is not due to a
generalized immunosuppressive effect.

C.   Effect of Treatment with p55-sf2 in Conjunction with
      Anti-CD4 Antibody

15   In view of the high titres of antibodies to p55-sf2
that were detected in mice treated with the fusion
protein, an experiment was carried out to determine
whether concurrent administration of anti-CD4 monoclonal
antibody (mAb) could enhance the therapeutic effects of
20 p55-sf2. Using the Experimental Procedure described
above, a comparison was made of three different treatment
regimes: anti-CD4 mAb alone (200 μg), p55-sf2 alone (100
μg) or anti-CD4 mAb (200 μg) plus p55-sf2 (100 μg). A
fourth group consisted of untreated control mice. The
25 cell-depleting anti-CD4 mAb (rat IgG2b) consisted of a 1:1
mixture of YTS 191.1.2 and YTA 3.1.2, provided by H.
Waldmann (University of Cambridge, UK) (Galfre, G. et al.,
Nature 277: 131-133 (1979); Cobbold, S.P. et al., Nature
312: 548-551 (1984); Qin, S. et al., European J.
30 Immunology 17:1159-1165 (1987)). p55-sf2 is described
above.

-31-

Paw-Swelling

Treatment with p55-sf2 alone resulted in a marked inhibition of paw-swelling, but the synergistic inhibitory effect of anti-CD4 mAb in combination with p55-sf2 was
5 remarkable. In contrast, anti-CD4 mAb treatment alone had very little effect on paw-swelling.

Limb Involvement

As before, the progressive involvement of additional limbs following the initial appearance of arthritis was
10 studied. Results are shown in Table 7.

Table 7: Anti-CD4 Antibody and p55-sf2 Prevent New Limb
Recruitment

	Treatment (number of animals)	Limbs Affected (mean ± SEM)		Increase (%)
		Day 1	Day 10	
15	Control (n = 6)	1.17 ± 0.17	2.00 ± 0.26	71%
	Anti-CD4 mAb (n = 6)	1.17 ± 0.17	1.83 ± 0.31	56%
	p55-sf2 (n = 7)	1.43 ± 0.20	1.71 ± 0.18	19%
20	Anti-CD4 mAb/ p55-sf2 (n = 6)	1.33 ± 0.21	1.33 ± 0.21[1]	0%

[1] P < 0.05 (vs. controls; Mann Whitney test).

There was a mean increase in limb involvement of 71% in the control group, which was reduced to 56% in the group given anti-CD4 mAb alone, and only 19% in the group given
25 p55-sf2. However, in the group given anti-CD4 mAb plus p55-sf2, the increase in limb involvement was 0%, a statistically significant difference.

-32-

Histology

Histological analysis of PIP joints of treated mice
was carried out as described above. Results are shown in
Table 8.

5 **Table 8:** Effects of Anti-CD4 mAb and p55-sf2 in the
Prevention of Joint Erosion

Treatment	PIP Joints with Erosions
Control	6/6 (100%)
Anti-CD4 mAb	6/6 (100%)
p55-sf2	2/6 (33%)[1]
Anti-CD4 mAb plus p55-sf2	1/6 (17%)[2]

[1] P = 0.06 (vs. control)
[2] P < 0.05 (vs. control) Data were compared by the
Fisher exact test.

15 The control group and the group given anti-CD4 mAb alone
gave identical results, with 6/6 (100%) of PIP joints in
both groups showing significant erosions. However, in the
group given p55-sf2 alone, only 2/6 (33%) of PIP joints
showed erosions. Only 1/6 (17%) of joints showed erosions
20 in the group given anti-CD4 plus p55-sf2.

Antibody responses to p55-sf2

The IgM/IgG responses to injected p55-sf2 were
measured by ELISA at the end of the treatment period (day
10). Microtitre plates were coated with p55-sf2
25 (5 µg/ml), blocked, then incubated with serially diluted
test sera. Negative controls consisted of sera from
saline-treated mice. Bound IgM or IgG were detected by
the appropriate goat anti-mouse Ig-alkaline phosphatase
conjugate, followed by substrate. Results are shown in
30 Table 9.

-33-

Table 9: Anti-p55-sf2 Responses and Levels of Free p55-sf2 in Sera of Mice Treated with p55-sf2 Alone or in Combination with Anti-CD4 mAb

Treatment	Anti-p55-sf2 Response (titres)		p55-sf2 Level
	IgM	IgG	
Experiment 1			
saline	1:20	1:35	-
p55-sf2, 2 μg	1:50	1:590	< 0.2 μg/ml
p55-sf2, 20 μg	1:2?	1:3924	< 0.2 μg/ml
p55-sf2, 100 μg	1:256	1:5280	< 0.2 μg/ml
Experiment 2			
p55-sf2, 100 μg	1:336	1:5100	< 0.2 μg/ml
p55-sf2, 100 μg, plus anti-CD4 mAb	1:15	1:200	12.3 ± 1.1 μg/ml

High titres of both IgM and IgG antibodies to p55-sf2 were
20 detected in treated mice, with the highest titres being
found in the mice given the 100 μg dose. These results
indicate that p55-sf2, which is derived from human
proteins, is highly immunogenic in mice. This may account
for the slightly greater efficacy of anti-TNF mAb _in vivo_
25 described in Section B, above, despite the higher
neutralizing titre of the fusion protein _in vitro._
Anti-CD4 mAb treatment was found to block almost
completely the formation of both IgM and IgG antibodies to
p55-sf2.

-34-

Serum Levels of Free p55-sf2

Microtitre plates were coated with recombinant murine
TNF-α (Genentech Inc., San Francisco, CA), blocked, then
incubated with test sera. Goat anti-human IgG-alkaline
5 phosphatase conjugate was then applied followed by
substrate. Quantitation was by reference to a sample of
known concentration of p55-sf2.

The inhibition of the antibody response was
associated with pronounced differences in the circulating
10 levels of p55-sf2 in treated mice. Thus, free p55-sf2 was
undetectable in mice given the fusion protein alone,
whereas in the mice given anti-CD4 mAb plus p55-sf2, the
mean serum level of p55-sf2 was 12.3 μg/ml.

EXAMPLE 3 Treatment of Induced Arthritis in a Murine Model
15   using Cyclosporin A and Anti-TNF Antibody

The murine model of collagen type II induced
arthritis, described above, was used to investigate the
efficacy of the CD4+ T cell inhibiting agent cyclosporin A
in conjunction with anti-TNF monoclonal antibody (mAb),
20 for the ability to modulate the severity of joint disease
in collagen-induced arthritis. A comparison was made
between the efficacy of treatment with cyclosporin A
(CsA), anti-TNF antibody, and combination of CsA and anti-
TNF antibody.

25 A.   Experimental Procedure

Male DBA/1 mice were immunized intradermally with
100 μg of bovine type II collagen emulsified in complete
Freund's adjuvant (Difco Laboratories, East Molsey, UK).
The mean day of onset of arthritis was approximately one
30 month after immunization. After the onset of clinically

evident arthritis (erythema and/or swelling), groups of
mice (11 mice each) were subjected to treatment with one
of the following therapies: 50 µg (2 mg/kg) L2 (the
isotype control for anti-TNF antibody), intraperitoneally
5 once every three days (days 1, 4 and 7); 250 µg (10 mg/kg)
cyclosporin A intraperitoneally daily; 50 µg (2 mg/kg)
anti-TNF mAb TN3-19.12, intraperitoneally once every three
days (days 1, 4 and 7); or 250 µg cyclosporin A
intraperitoneally daily in conjunction with 50 µg anti-TNF
10 mAb intraperitoneally once every three days. Arthritis
was monitored for paw swelling (measured with calipers)
for 10 days, after which the mice were sacrificed and
joints were processed for histology.

Paw-Swelling

15   Treatment with cyclosporin A in conjunction with
anti-TNF mAb resulted in a reduction in paw-swelling over
the treatment period, relative to mice treated with
control antibody. Results are shown in Figure 3.

Limb Involvement

20   As before, the progressive involvement of additional
limbs following the initial appearance of arthritis was
studied. Results are shown in Table 10.

-36-

Table 10: Anti-CD4 Antibody and p55-sf2 Prevent New Limb Recruitment

Treatment	Limbs Affected (mean ± SEM)		Increase (%)
	Day 1	Day 10	
Control mAb	1.36 ± 0.20	2.45 ± 0.28	80.1%
Cyclosporin A	1.36 ± 0.15	2.18 ± 0.30	60.3%
Anti-TNF mAb	1.45 ± 0.16	1.9 ± 0.21	31.0%
CsA/Anti-TNf mAb	1.27 ± 0.14	1.54 ± 0.20[1]	21.0%

[1] P = 0.03 (vs. control).

Treatment with cyclosporin A in conjunction with anti-TNF mAb resulted in statistically significant reductions in limb involvement in comparison to control monoclonal antibody (P = 0.03).

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

-37-

CLAIMS

What is claimed is:

1. A method of treating autoimmune or inflammatory
    disease in a mammal comprising administering to said
    mammal a therapeutically effective amount of a
    combination of a CD4+ T cell inhibiting agent and a
    TNF antagonist.

2. A method of Claim 1, wherein the CD4+ T cell
    inhibiting agent is administered simultaneously with
    the TNF antagonist.

3. A method of Claim 1, wherein the CD4+ T cell
    inhibiting agent is administered sequentially with
    the TNF antagonist.

4. A method of Claim 1, wherein the CD4+ T cell
    inhibiting agent and the TNF antagonist are
    administered by a route selected from the group
    consisting of: subcutaneously, intravenously, and
    intramuscularly.

5. A method of Claim 1, wherein the CD4+ T cell
    inhibiting agent and the TNF antagonist are
    administered in a pharmaceutically acceptable
    vehicle.

6. A method of Claim 1, wherein an anti-inflammatory
    agent is administered in conjunction with the CD4+ T
    cell inhibiting agent and the TNF antagonist.

-38-

7.   A method of Claim 6, wherein the anti-inflammatory
        agent is an agent interfering with the activity or
        synthesis of TNF.

8.   A method of Claim 6, wherein the anti-inflammatory
5   agent is an agent interfering with the activity or
        synthesis of IL-1.

9.   A method of Claim 6, wherein the anti-inflammatory
        agent is an agent interfering with the activity or
        synthesis of IL-6.

10 10.   A method of Claim 6, wherein the anti-inflammatory
        agent is a cytokine with anti-inflammatory
        properties.

11.   A method of Claim 1, wherein the autoimmune disease
        is rheumatoid arthritis.

15 12.   A method of Claim 1, wherein the CD4+ T cell
        inhibiting agent is an antibody to T cells or to T
        cell receptors.

13.   A method of Claim 1, wherein the CD4+ T cell
        inhibiting agent is an antibody to an antigen
20   presenting cell or to the receptors of an antibody
        presenting cell.

14.   A method of Claim 1, wherein the CD4+ T cell
        inhibiting agent is a peptide or small molecule which
        inhibits T cell interaction with antigen presenting
25   cells.

-39-

15. A method of treating autoimmune or inflammatory
     disease in a mammal comprising administering to said
     mammal a therapeutically effective amount of a
     combination of a CD4+ T cell inhibiting agent and an
 5   inflammatory mediator.

16. A method of Claim 15, wherein the inflammatory
     mediator is agent interfering with the activity or
     synthesis of TNF.

17. A method of Claim 15, wherein the inflammatory
10   mediator is an agent interfering with the activity or
     synthesis of IL-1.

18. A method of Claim 15, wherein the inflammatory
     mediator is an agent interfering with the activity or
     synthesis of IL-6.

15 19. A method of Claim 15, wherein the inflammatory
     mediator is a cytokine with anti-inflammatory
     properties.

20. A method of treating autoimmune or inflammatory
     disease in a mammal, comprising administering to said
20   mammal a therapeutically effective amount of a
     combination of anti-CD4 antibody and anti-TNF
     antibody.

21. A method of treating autoimmune or inflammatory
     disease in a mammal, comprising administering to said
25   mammal a therapeutically effective amount of a
     combination of anti-CD4 antibody and soluble TNF
     receptor.

-40-

22. A method of treating autoimmune or inflammatory
    disease in a mammal, comprising administering to said
    mammal a therapeutically effective amount of a
    combination of anti-CD4 antibody and TNF receptor/IgG
5   fusion protein.

23. A method of treating autoimmune or inflammatory
    disease in a mammal, comprising administering to said
    mammal a therapeutically effective amount of a
   combination of cyclosporin A and anti-TNF antibody.

Fig.1A

Fig.1B

2/4

Fig.2A

Fig.2B

3/4

Fig.2C

Fig.2D

4/4

Fig.3

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6   A61K39/395   //(A61K39/395,37:02)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LYMPHOKINE AND CYTOKINE RESEARCH vol. 12, no. 4 , August 1993 , NEW YORK NY, USA pages 261 - 263 P. RALPH 'Clinical and preclinical studies presented at the Keystone symposium on arthritis, related diseases, and cytokines.' see the whole document --- -/--	1-22

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
31 May 1994	14. 06. 94

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Nooij, F

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT vol. 0, no. 17 B , 1993 , NEW YORK NY, USA page 145 M. ELLIOTT ET AL. 'Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to IFN-alpha: Safety, clinical efficacy and control of the acute phase response.' see abstract EZ 405 ---	1-6, 11-16, 20,21
Y	CLINICAL AND EXPERIMENTAL RHEUMATOLOGY vol. 10, no. 4 , July 1992 , PISA, ITALY pages 365 - 374 E. RACADOT ET AL. 'Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5).' see abstract ---	1-6, 11-16, 20,21
Y	CYTOKINE vol. 3, no. 3 , May 1991 , BASEL, SWITZERLAND pages 266 - 267 G. HORNEFF ET AL. 'Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis.' see the whole document ---	1-21
Y	THE LANCET vol. 2, no. 8657 , 29 July 1989 , LONDON, GB pages 244 - 247 F. BRENNAN ET AL. 'Inhibitory effect of TNFalpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.' see the whole document ---	1-21
Y	WO,A,89 08460 (CELLTECH LIMITED) 21 September 1989 see claims --- -/--	1-21,23

1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCANDINAVIAN JOURNAL OF IMMUNOLOGY vol. 34, no. 5 , November 1991 , OXFORD, GB pages 627 - 633 D. STEINBRÜCHEL ET AL. 'Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporin A has a positive but not simple dose-dependent effect on rat renal allograft survival.' see abstract ---	1-21,23
T	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA vol. 91, no. 7 , 29 March 1994 , WASHINGTON DC, USA pages 2762 - 2766 R. WILLIAMS ET AL. 'Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.' see the whole document ---	1-22
P,X	ZEITSCHRIFT FüR RHEUMATOLOGIE vol. 52, no. 6 , November 1993 , DARMSTADT, GERMANY pages 365 - 382 E. SCHACHT 'Gegenwärtige und zukünftige Therapiestrategien der rheumatoiden Arthritis.' see page 365, left column, line 22 - line 29 see page 372, left column, line 26 - right column, line 6 see page 374, left column, line 42 - right column, line 52 -----	1-23

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-8908460	21-09-89	EP-A-	0403558	27-12-90
		GB-A-	2233559	16-01-91
		JP-T-	3503890	29-08-91
		US-A-	5183657	02-02-93